<DOC>
	<DOCNO>NCT02414334</DOCNO>
	<brief_summary>Rationale : SABR ( Stereotactic ablative radiotherapy ) one standard treatment option besides surgical resection limit lung metastasis ( oligometastases ) colorectal cancer . High efficacy term local control metastatic lesion treat show . Nevertheless , precise effect SABR upon progression-free- overall survival patient unknown . To evaluate develop local treatment option metastatic disease , information necessary regard impact upon - pattern - disease progression local treatment option SABR . Objective : To determine effect upon progression free survival upon tumorload relative baseline , one year randomisation immediate SABR versus delay SABR ( scan-and-personalise policy ) . Secondarily , pattern progression , patient-reported symptom quality life monitor .</brief_summary>
	<brief_title>SABR-SCAN Trial Pulmonary Oligometastases</brief_title>
	<detailed_description />
	<criteria>Age ≥ 18 year WHOPerformance status ( WHOPS ) 0 1 Patients 1 3 lung metastasis 8 mm 3 cm , colorectal cancer . Resection consider multidisciplinary conference recommend refused patient . Possibility define target lesion fulfil follow criterion : No lesion large 3 cm ; Not 3 metastasis ≥ 8 mm total ( lesion small 8 mm diameter NOT count NOT irradiate ) ; No prior radiotherapy ( SABR ) within 2 cm target lesion ( i.e. , distance prior planningtargetvolume ( PTV ) actual intend PTV 2 cm AND dose distribution former radiation permit SABR ) . Primary tumour completely remove surgically . Metastases outside target organ ( e.g . liver metastasis ) radically treat locally ( resection , radiofrequency ablation ( RFA ) , microwave ablation ( MWA ) , stereotactic radiotherapy , ) . Earlier resect ablated ( SABR , RFA , MWA ) metastases lung , liver , organ form exclusion criterion . Brain metastases completely resect treat stereotactic radiosurgery . Bone metastases resect treated high dose radiotherapy ( equivalent &gt; 40 Gy ) asymptomatic . Patients reproductive potential must agree practice effective contraceptive method . Women childbearing potential must pregnant lactating . Proficiency Dutch language qualityoflife questionnaire complete Dutch absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial . Before patient randomisation , informed consent must give accord International Conference Harmonisation Technical Requirements Registration Pharmaceuticals Human Use ( ICH ) European Union ( EU ) accordance good clinical practice ( GCP ) , national/local regulation . Any clinical symptom possibly certainly cause index lungmetastases Physical inability undergo stereotactic radiotherapy ( e.g. , serious shoulder stiffness ) Any uncontrolled malignancy index colorectal cancer Other malignancy within recent two year , even completely control ( control = evidence disease ) Failure comply inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Oligometastases</keyword>
	<keyword>Stereotactic ablative radiotherapy ( SABR )</keyword>
	<keyword>Metastatic tumour</keyword>
</DOC>